Vincerx Pharma
Vincerx Pharma is a clinical-stage biopharmaceutical company developing cancer therapies for oncology patients, headquartered in Palo Alto, California, and publicly traded on NASDAQ under the ticker VINC.
- Company typePublic
- Founded2018
- HeadquartersPalo Alto, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Vincerx Pharma does
Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company headquartered at 260 Sheridan Avenue, Suite 400, Palo Alto, California, founded in 2018 and publicly traded on NASDAQ under the ticker VINC. The company is focused on developing therapeutic candidates for cancer patients, with a pipeline described as being in various phases of clinical development, though no specific named drug candidates, mechanism-of-action details, or platform architecture are disclosed in the available source material. The company is founder-led, with Ahmed M. Hamdy serving as Founder and Chief Executive Officer, supported by Raquel Izumi as President and Chief Operating Officer and Tom Thomas as General Counsel and Chief Legal Officer; headcount is reported in the 11–50 range.
Vincerx Pharma firmographics
Firmographics- Name
- Vincerx Pharma
- Legal name
- Vincerx Pharma, Inc.
- Website
- https://vincerx.com
- Company type
- Public
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Vincerx Pharma is a clinical-stage biopharmaceutical company developing cancer therapies for oncology patients, headquartered in Palo Alto, California, and publicly traded on NASDAQ under the ticker VINC.
- Ownership category
- akta.pro rank
Vincerx Pharma industry classification
Industry- Product category
- Clinical-Stage Oncology Biopharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)
- akta.pro secondary industry
- Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)
Keywords
Where Vincerx Pharma is headquartered
LocationHeadquarters
- HQ city
- Palo Alto
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Vincerx Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Vincerx Pharma product offering
Product offeringCore offering
Vincerx Pharma is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies. The company researches and advances oncology drug candidates through preclinical and clinical development stages, with the goal of bringing novel targeted therapeutics to cancer patients. It is currently in a clinical-stage phase with no marketed products.
Product overview
Vincerx Pharma is a clinical-stage biopharmaceutical company focused on developing therapies for cancer patients. The company has a pipeline of candidates in various phases of clinical development. No specific named drug products or therapeutic candidates are identified in the available sources.
Differentiator
Problem solved
Functional benefit
Products and services
- Clinical-stage oncology pipeline
Companies that use Vincerx Pharma
Customer profileSegments1 record
Ideal customer profiles1 record
Vincerx Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Vincerx Pharma partnerships and signals
Strategic signalScale indicators2 records
Recent moves4 records
Expansion highlights2 records
Vincerx Pharma competitors and assessment
Company assessmentDirect peers
- Erasca: Erasca is a clinical-stage precision oncology company developing therapies targeting the RAS/MAPK pathway. Comparable to Vincerx as a small public clinical-stage oncology developer with multiple candidates in early-phase trials.
- Cogent Biosciences: Cogent Biosciences is a clinical-stage biotech focused on precision therapies for genetically defined diseases including oncology. Similar small-cap public clinical-stage profile with focused oncology pipeline.
- Black Diamond Therapeutics: Black Diamond Therapeutics is a clinical-stage oncology company using a proprietary discovery platform to develop precision medicines for genetically defined cancers. Matches Vincerx's small clinical-stage oncology positioning.
- Theseus Pharmaceuticals: Theseus Pharmaceuticals was a clinical-stage biopharmaceutical company developing targeted oncology therapies. Comparable clinical-stage oncology business model and scale, though now in wind-down mode.
- Foghorn Therapeutics: Foghorn Therapeutics is a clinical-stage precision oncology company developing medicines targeting the chromatin regulatory system. Similar small public clinical-stage structure with platform-based oncology pipeline.
- Kymera Therapeutics: Kymera Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degradation therapies for cancer and immunological diseases. Comparable clinical-stage oncology focus with public listing.
Emerging players
- Compugen: Compugen is a clinical-stage cancer immunotherapy company leveraging a computational platform to discover drug targets and develop therapeutics. Similar clinical-stage oncology focus with computational discovery angle.
- Atreca: Atreca is a clinical-stage biotechnology company developing immuno-oncology therapeutics. Small clinical-stage oncology developer with limited cash runway comparable to Vincerx's situation.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Vincerx Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vincerx Pharma leadership team
Management profileNumber of profiles
Profiles3 records
Vincerx Pharma funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vincerx Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vincerx Pharma
What does Vincerx Pharma do?
Vincerx Pharma is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies. The company researches and advances oncology drug candidates through preclinical and clinical development stages, with the goal of bringing novel targeted therapeutics to cancer patients. It is currently in a clinical-stage phase with no marketed products.
Is Vincerx Pharma a public or private company?
Vincerx Pharma is a public company. It is classified as public and is currently operating.
When was Vincerx Pharma founded?
Vincerx Pharma was founded in 2018. It employs 11 to 50 people.
Where is Vincerx Pharma based?
Vincerx Pharma is headquartered in Palo Alto, United States, in the North America region.
Who are Vincerx Pharma's main competitors?
Direct peers on record are Erasca, Cogent Biosciences, Black Diamond Therapeutics, Theseus Pharmaceuticals, Foghorn Therapeutics and Kymera Therapeutics. Emerging players are Compugen and Atreca.
Does Vincerx Pharma have an API?
No public API is recorded for Vincerx Pharma.
What industry is Vincerx Pharma in?
Vincerx Pharma's product category is Clinical-Stage Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution), with a secondary code of HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics. Its NAICS code is 3254 and its SIC code is 2834.